Annual report pursuant to Section 13 and 15(d)

Related Party Transactions - Additional Information (Detail)

Related Party Transactions - Additional Information (Detail)							12 Months Ended
	Nov. 08, 2017 USD ($) Investor $ / shares shares	May 10, 2017 Investor	Dec. 29, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($) Investor shares	Jun. 27, 2016 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 15, 2016	Sep. 14, 2016
Related Party Transaction [Line Items]
Number of accredited investors \| Investor		3
Cash received from sale of business								$ 1,450,000
Cash received from related parties								250,000
Share issued during period, value								2,640,147
Accounts payable and accrued expenses							$ 39,457	524,620
Maximum [Member] \| Oral Mucositis ECC [Member]
Related Party Transaction [Line Items]
Debt instrument, term							12 months
Series B Preferred Stock [Member]
Related Party Transaction [Line Items]
Convertible shares Preferred stock, number of common stock upon conversion \| shares	1,320,000
Convertible preferred stock, terms of conversion	Conversion of one share of Series B Preferred Stock into two shares of Common Stock.
Reverse stock split, conversion ratio of Preferred stock into Common stock	2
Purchase price per share of Preferred Stock, as per share of Common Stock \| $ / shares	$ 2.50
Common Stock [Member]
Related Party Transaction [Line Items]
Share issued during period, value								$ 905
Intrexon [Member]
Related Party Transaction [Line Items]
Percentage of outstanding common stock								31.50%
Intrexon [Member] \| Lantibiotic ECC [Member]
Related Party Transaction [Line Items]
Cash paid to Intrexon Corporation							$ 594	$ 548,994
Intrexon [Member] \| Oral Mucositis ECC [Member]
Related Party Transaction [Line Items]
Cash paid to Intrexon Corporation							524,026	932,645
Intrexon [Member] \| Unsecured Non-convertible Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount	$ 2,400,000
Debt instrument, converted amount	$ 3,400,000
Debt instrument, term		2 years
Interest rate		12.00%
Intrexon [Member] \| Series C Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of share issued as a result of conversion of convertible securities \| shares	100
Intrexon [Member] \| Series C Preferred Stock [Member] \| Lantibiotic ECC [Member]
Related Party Transaction [Line Items]
Share issued during period, value							1,188
Intrexon [Member] \| Series C Preferred Stock [Member] \| Oral Mucositis ECC [Member]
Related Party Transaction [Line Items]
Share issued during period, value							763,189
ProBiora Health, LLC [Member]
Related Party Transaction [Line Items]
Cash received from related parties							$ 10,388	$ 26,333
ProBiora Health, LLC [Member] \| Transition Services Agreement [Member]
Related Party Transaction [Line Items]
Management fee							3.00%
Agreement term							90 days
Subletting rate per month							$ 1,623
Sublease expiration date							Feb. 28, 2017
ProBiora Health, LLC [Member] \| Discontinued Operations Disposed of by Sale [Member]
Related Party Transaction [Line Items]
Interest rate						1.00%
Sales price of business						$ 1,700,000
Cash received from sale of business						1,250,000
Receivable from sale of business						$ 450,000
Contingent consideration payment period						10 years
ProBiora Health, LLC [Member] \| Discontinued Operations Disposed of by Sale [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Contingent consideration						$ 2,000,000
KFLP [Member]
Related Party Transaction [Line Items]
Percentage of outstanding common stock								34.50%
Principal Owner [Member] \| Intrexon [Member]
Related Party Transaction [Line Items]
Percentage of outstanding common stock							32.00%	32.00%
Accounts payable and accrued expenses							$ 39,457	$ 524,620
Private Placement [Member] \| Series B Preferred Stock [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of convertible preferred stock	$ 3,300,000
Number of accredited investors \| Investor	4
Warrants to purchase common stock \| shares	1,064,518
Private Placement [Member] \| Fall 17 Warrant [Member] \| Series B Preferred Stock [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock \| shares	1,064,518
Term of warrants	7 years
Non-exercisable term of warrants	6 months
Warrants exercise price per share \| $ / shares	$ 3.10
Private Placement [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Number of accredited investors \| Investor					3
Issuance date					Jun. 30, 2016
Shares issued \| shares					904,568
Proceeds from issuance					$ 4,667,000
Private Placement [Member] \| Common Stock [Member] \| Dr. Frederick Telling [Member]
Related Party Transaction [Line Items]
Shares issued \| shares					96,918
Private Placement [Member] \| Intrexon [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Shares issued \| shares					226,142
Private Placement [Member] \| KFLP [Member]
Related Party Transaction [Line Items]
Interest rate									6.00%	3.00%
Cash received from related parties			$ 1,000,000	$ 1,000,000
Extended maturity date of notes payable								Dec. 31, 2016
Private Placement [Member] \| KFLP [Member] \| Series B Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of convertible preferred stock and warrants purchased by investors \| shares	1,500,000
Warrants to purchase common stock \| shares	241,936
Private Placement [Member] \| KFLP [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Interest rate					3.00%				6.00%	3.00%
Shares issued \| shares					581,508
Note receivable due from sale of common stock					$ 2,000,000
Cash received from related parties			$ 1,000,000	$ 1,000,000
Extended maturity date of notes payable								Dec. 31, 2016